RBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $190

Benzinga · 3d ago
RBC Capital analyst Brian Abrahams maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and raises the price target from $187 to $190.